OrganOx logo

OrganOx

"Living Organs For Life" Transforming transplantation with the OrganOx metra®. A transportable, automated ex vivo liver perfusion device. The core technology employed by the OrganOx metra® has been in development for over 15 years. During this time both of the founders (Professor Peter Friend and Professor Constantin Coussios) have driven the development of organ preservation and maintenance, formerly at the University of Cambridge and latterly at the University of Oxford. OrganOx Limited was founded in April 2008 as a spin-out from the University of Oxford. Conventional cold preservation involves storage of the liver at 4˚C, using a non-physiological perfusion solution that aims to minimise liver decay. By contrast, warm preservation seeks to re-create an environment that mimics the human body by continuously perfusing at physiological pressures and flows with oxygen-carrying red cells at 37˚C and providing nutrition. The liver is therefore functional during the preservation period, producing bile, metabolizing glucose and maintaining a physiological pH. This enables objective assessment of organ performance prior to transplant, extended preservation times, and the potential use of organs that are presently being discarded.

https://www.organox.com/
51-200 employees
OrganOx logo

OrganOx

OrganOx is a medical technology company focused on improving organ transplantation outcomes by preserving and assessing donor organs using its normothermic machine perfusion (NMP) platform.

Company Size

51-200 employees

Location

United Kingdom

About

"Living Organs For Life" Transforming transplantation with the OrganOx metra®. A transportable, automated ex vivo liver perfusion device. The core technology employed by the OrganOx metra® has been in development for over 15 years. During this time both of the founders (Professor Peter Friend and Professor Constantin Coussios) have driven the development of organ preservation and maintenance, formerly at the University of Cambridge and latterly at the University of Oxford. OrganOx Limited was founded in April 2008 as a spin-out from the University of Oxford. Conventional cold preservation involves storage of the liver at 4˚C, using a non-physiological perfusion solution that aims to minimise liver decay. By contrast, warm preservation seeks to re-create an environment that mimics the human body by continuously perfusing at physiological pressures and flows with oxygen-carrying red cells at 37˚C and providing nutrition. The liver is therefore functional during the preservation period, producing bile, metabolizing glucose and maintaining a physiological pH. This enables objective assessment of organ performance prior to transplant, extended preservation times, and the potential use of organs that are presently being discarded.

Needs Assessment

Active buying signals and potential business opportunities

Technology Requirements

Normothermic machine perfusion (NMP) technology

Technologies to improve organ preservation and assessment

Improved liver preservation methods

Functional liver assessment technology

Service Requirements

Customer support

Training for using the OrganOx metra

Support and maintenance for the OrganOx metra device

Clinical Affairs and Training initiatives

Infrastructure Requirements

Fully automated, easy-to-use, and transportable device

Integration into existing transplant procedures and logistics

Integration into existing transplant center infrastructure

Integration with transplant logistics

Talent Requirements

Expertise in medical device engineering

Clinical expertise in organ transplantation

Regulatory affairs expertise for FDA and CE mark compliance

AI Insights

Growth Trajectory

With a recent $142 million equity financing and approvals for liver transplantation in multiple regions, OrganOx demonstrates strong growth potential, particularly as it expands into kidney transplantation and explores xenotransplantation.

Market Opportunity

OrganOx's innovative normothermic machine perfusion technology provides a significant market opportunity by addressing the critical shortage of transplantable organs and improving patient outcomes compared to traditional preservation methods.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats